Progress of clinical study on renal anemia treated with single dosage of recombinant human erythropoietin

doi:10.3877/cma.j.issn.2095-3216.2015.01.010

Abstract

Abstract:

Anemia is the most common complication in the progression of chronic kidney disease (CKD). Erythropoietin is a kind of glycoprotein mainly produced by the kidney, and regulates production of erythrocytes. The lack of erythropoietin is the important reason for renal anemia. Multiple studies showed treatment with a single high dosage (10 000 IU/time) of recombinant human erythropoietin (rHuEPO) is effective and safe in patients with hemoglobin levels lower than the standard. This present paper reviewed the current status of hemoglobin levels in renal anemic patients, pharmacokinetic characteristics of different doses of rHuEPO, and related clinical applications and advancement.

Key words: Renal anemia, Chronic kidney disease, Recombinant human erythropoietin, Dosage

Cunhai Chen, Yanmei Song. Progress of clinical study on renal anemia treated with single dosage of recombinant human erythropoietin[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(01): 49-51.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2015.01.010

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2015/V04/I01/49

Figures/Tables 1

References 21

[1]	何婷，毛海萍，李志斌，等. 贫血加重IgA肾病患者的临床和病理改变[J]. 中华肾脏病杂志，2012, 28(6): 460-463.
[2]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey [J]. Lancet, 2012, 379(9818): 815-822.
[3]	Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States [J]. PLoS One, 2014, 9(1): e84943.
[4]	Moreno F, Sanz-Guajardo D, López-Gómez JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology [J]. J Am Soc Nephrol, 2000, 11(2): 335-342.
[5]	KDIGO. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease [J]. J Int Soc Nep, 2012, 2(4): 279-335.
[6]	中国医师协会肾内科医师分会肾性贫血诊断和治疗共识专家组．肾性贫血诊断与治疗中国专家共识(2014修订版)[J]．中华肾脏病杂志，2014，30(9)：712-716.
[7]	黄雯，陈粲，张国娟. 2007年北京市血液透析患者血红蛋白达标情况分析[J]. 中国血液净化，2010, 9(5): 285-287.
[8]	张伟明，钱家麒. 上海市透析登记及其结果分析[J]. 中国血液净化，2012, 11(5): 233-236.
[9]	Bárány P, Müller HJ. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease [J]. Nephrol Dial Transplant, 2007, 22 (Suppl l4): iv10-iv18.
[10]	Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients[J]. Clin J Am Soc Nephrol, 2009, 4(1): 33-38.
[11]	于阳，李学旺，朱珠，等. 健康志愿者单剂量静脉应用促红细胞生成素的生物利用度和生物等效性[J]. 中国医学科学院学报，2001, 23(3): 237-238.
[12]	Ramakrishnan R, Cheung WK, Wacholtz MC, et al. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers [J]. J Clin Pharmacol, 2004, 44(9): 991-1002.
[13]	Locatelli F, Baldamus CA, Villa G, et al. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study [J]. Am J Kidney Dis, 2002, 40(1): 119-125.
[14]	中华医学会肾脏病学分会. 重组人促红细胞生成素在肾性贫血中合理应用的专家共识[J]．中国血液净化，2007，6(8)：440-443.
[15]	向允禧，蒋琼，钟爱民，等. 大剂量低频率使用重组人促红细胞生成素临床对照研究[J]. 江西医药，2011, 46(5): 399-401.
[16]	顾勇，施雪枫. 大剂量重组人促红细胞生成素治疗血透患者肾性贫血的疗效与安全性[J]. 中国临床药学杂志，2004, 13(2): 69-72.
[17]	马丽杰. 不同剂量重组人促红细胞生成素治疗肾性贫血疗效观察[J]. 中国临床实用医学，2009, 3(12)：81-82.
[18]	张林，黄胜，雷治国，等. 大剂量基因重组人促红细胞生成素治疗肾性贫血的疗效观察[J]. 临床肾脏病杂志，2006, 6(5): 241.
[19]	Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease [J]. Clin Nephrol, 2004, 61(6): 392-405.
[20]	Pergola PE, Gartenberg G, Fu M, et al. A randomized controlled study of weekly and biweekly dosing of epoetinalfa in CKD Patients with anemia [J]. Clin J Am Soc Nephrol, 2009, 4(11): 1731-1740.
[21]	Lee YK, Kim SG, Seo JW, et al. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study [J]. Nephrol Dial Transplant, 2008, 23(10): 3240-3246.

Please choose a citation manager

Content to export